🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

22 recruiting trials

for Epidermolysis Bullosa

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB) NCT06563414n/a1 site📍 Pittsburgh Krystal Biotech, Inc. A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting NCT07700966n/a4 sites📍 Palo Alto📍 Aurora📍 Chicago Abeona Therapeutics, Inc · Tests: Prademagene Zamikeracel GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment NCT07193134Phase 1, Phase 21 site📍 Toronto CHU de Quebec-Universite Laval · Tests: Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS) Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa NCT07482787Phase 34 sites📍 Rancho Santa Margarita📍 Redwood City📍 Philadelphia Paradigm Therapeutics · Tests: SD-101 Dermal Cream (6%), Vehicle (SD-101 0%) A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized NCT06509984Phase 24 sites📍 Nice📍 Paris📍 Paris Centre Hospitalier Universitaire de Nice · Tests: Apremilast treatment Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin NCT06731933Phase 22 sites📍 Redwood City📍 Bari Stanford University · Tests: BVEC Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa NCT07230223Phase 1, Phase 21 site📍 Isfahan Isfahan University of Medical Sciences · Tests: Ev.FV 1.0 x 1011 par/ml Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa NCT01019148n/a1 site📍 Stanford Stanford University A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez NCT06423573n/a12 sites📍 Palo Alto📍 Aurora📍 Gainesville Chiesi Farmaceutici S.p.A. · Tests: Filsuvez Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling NCT06330350n/a1 site📍 Maastricht Maastricht University Medical Center · Tests: Qualitative interview Gentamicin for Junctional Epidermolysis Bullosa NCT03526159Phase 1, Phase 21 site📍 Los Angeles University of Southern California · Tests: Gentamicin Sulfate A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa NCT07016750Phase 35 sites📍 Rancho Santa Margarita📍 Coral Gables📍 Worcester Krystal Biotech, Inc. · Tests: KB803, Placebo A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex NCT07027345Phase 22 sites📍 Palo Alto📍 Chicago BioMendics, LLC · Tests: 5% TolaSure Topical Gel, Topical Placebo Gel MSC EVs in Dystrophic Epidermolysis Bullosa NCT04173650Phase 1, Phase 23 sites📍 Phoenix📍 Los Angeles📍 Philadelphia Aegle Therapeutics · Tests: AGLE-102 A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study NCT06594393Phase 213 sites📍 Cincinnati📍 Paris📍 Athens Xinnate AB · Tests: TCP-25 gel, Vehicle (placebo) A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa NCT07858422Phase 21 site📍 Tainan Energenesis Biomedical Co., Ltd. · Tests: ENERGI-F703EB Cream, Matched vehicle cream FARD (RaDiCo Cohort) (RaDiCo-FARD) NCT05954416n/a15 sites📍 Bobigny📍 Bordeaux📍 Bordeaux Institut National de la Santé Et de la Recherche Médicale, … A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa NCT06917690Phase 36 sites📍 Fukuoka📍 Fukuoka📍 Kobe Chiesi Farmaceutici S.p.A. · Tests: Oleogel-S10 Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa NCT06834035Phase 1, Phase 21 site📍 Redwood City M. Peter Marinkovich · Tests: Immunoglobulin G Impact of Body Positioning on EndoFLIP Measurements: A Comparative Study of Supine and Left Lateral Decubitus Positions NCT07780981NA1 site📍 Baltimore Johns Hopkins University · Tests: EndoFlip Long-Term Follow-up Protocol NCT04917887n/a3 sites📍 Rancho Santa Margarita📍 Redwood City📍 Coral Gables Krystal Biotech, Inc. Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders NCT05649098EARLY Phase 11 site📍 Chicago Northwestern University · Tests: Dupilumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy